Oestrogen patches (OP) to treat prostate cancer (PC) – Are different commercial brands interchangeable?

Background: Luteinising Hormone Releasing Hormone agonists (LHRHa) are used widely to treat PC. Transdermal oestrogen is an alternative, producing castrate levels of testosterone (T) but avoiding oestrogen-dependent LHRHa-associated toxicities particularly osteoporosis. Transdermal administration also bypasses first-pass hepatic metabolism and therefore should avoid the vascular toxicity of oral oestrogen.

Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Ruth E. Langley, Trinh Duong, Ian F. Godsland, Howard Kynaston, Roger Kockelbergh, Stuart D. Rosen, Abdulla A. Alhasso, David P. Dearnaley, Noel W. Clarke, Gordana Jovic, Robin Carpenter, Anna Bara, Andrew Welland, Mahesh K. Parmar, Paul D. Abel, on behal Tags: P179 Source Type: research